Vietnam to soon have modern, energy-saving vaccine factory

A large-scale vaccine factory in Vietnam will be built using the world's leading modern technology combined with the Net Zero goal.

On January 15, Vietnam Vaccine Joint Stock Company (VNVC) officially signed a contract to design the VNVC Vaccine and Biological Products Factory with Rieckermann Group (Germany) — the world's leading designer in the field of vaccine and pharmaceutical factories.

The VNVC Vaccine and Biological Products Factory has received a total investment of nearly 80 million USD.

To meet the high requirements from VNVC, Rieckermann has optimally utilised an area of ​​over 26,000 m2 in its design for a modern complex factory including vaccine and biological product production areas, animal breeding and research buildings, and other utility areas. All of which fully meet high international standards.

In particular, the vaccine and biological product production factory area must meet the high-level GMP standards of the EU, FDA, PIC/S, and WHO.

In particular, the entire factory is designed according to Leadership in Energy & Environmental Design (LEED) standards. This is a strict international standard for a comprehensive green construction project, protecting the environment, saving energy, and moving towards Net Zero according to the modern trend of the world.

This will be the first vaccine factory in Vietnam to meet this standard, achieving the goal of reducing Vietnam's total greenhouse gas emissions to zero by 2050.

The factory marks a new and important milestone in the sustainable development strategy for the Vietnamese vaccine industry, contributing to soon making Vietnam a vaccine-owning country to ensure health security and enhance the competitiveness of the Vietnamese pharmaceutical industry internationally.

Speaking at the signing ceremony, Jorge Domingo Guerra, Business Development Manager of Rieckermann Group, said that the VNVC Vaccine and Biological Production Factory project not only demonstrates outstanding development in the improvement of Vietnam's biopharmaceutical infrastructure but is also a significant step forward in addressing global health challenges.

Jorge Domingo Guerra committed that Rieckermann will provide VNVC with an innovative, high-class design that fully meets international standards and criteria for safety, effectiveness, and long-term sustainability, while ensuring continuous production of vaccines and important biological products using the world's leading modern technologies.

It is expected that upon being put into operation, the VNVC factory will cooperate with the world's leading vaccine manufacturers, participating in each step of the vaccine and biological product production process and moving towards receiving technology transfer for independent production.